Quick Facts
| Property | Value |
|---|---|
| Category | Immune-Modulating Peptide |
| Risk Level | Moderate/High |
| Administration | Subcutaneous Injection |
| Typical Frequency | 3–6 Days Weekly |
| Estimated Half-Life | Approximately 2 Hours |
| Primary Research Interest | Immune Regulation / Recovery / Inflammation Support |
This material is provided strictly for educational and informational purposes related to peptide research and immune-modulating compounds. Thymosin Alpha-1 is a biologically active peptide capable of altering immune system signaling and inflammatory pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 4.00 mg/mL
At this concentration:
• 0.5 mg = 0.125 mL (12.5 units)
• 1.0 mg = 0.250 mL (25.0 units)
• 1.5 mg = 0.375 mL (37.5 units)
2. Route of Administration
Thymosin Alpha-1 is most commonly administered as a subcutaneous injectable immune-modulating peptide.
- Primary Route: SubQ Injection
- Preferred Timing: Flexible timing depending on immune support goals
- Administration Notes: Frequently used intermittently rather than continuously year-round
3. Typical Research Protocols
- Product Strength: 4.00 mg/mL
- Typical Delivered Amount: 0.8–1.5 mg daily, 3–6 days weekly PRN
- Frequency: 3–6 days per week PRN for immune system support
- Cycle Length: Weeks 1–4: 1.0–1.5 mg daily; Weeks 5–8: 0.5–1.0 mg three times weekly; then 4 weeks off
- Special Notes: Thymosin Alpha-1 is an immune system modulator and regulator, not simply an immune booster. Individuals with autoimmune disorders should use caution, as symptoms may worsen. Additional caution is advised when combined with corticosteroids, biologics, chemotherapy, or anti-rejection medications because TA1 may interfere with intended immune suppression strategies.
4. Summary
Thymosin Alpha-1 (TA1) is an experimental immune-modulating peptide researched for its effects on immune regulation, inflammatory signaling, and immune resilience.
Research interest in TA1 primarily centers around immune support, infection response, recovery enhancement, and modulation of immune system balance.
5. Mechanism of Action
TA1 is believed to influence immune signaling pathways involving T-cell function, cytokine signaling, and immune system regulation.
- Enhanced T-cell activity
- Improved immune signaling coordination
- Modulation of inflammatory pathways
- Potential antiviral immune support
- Improved immune resilience signaling
The compound is generally discussed as an immune regulator rather than a simple immune stimulant.
6. Potential Benefits
- Potential immune system support
- Improved recovery from illness
- Potential antiviral support signaling
- Enhanced immune resilience
- Possible inflammatory regulation support
7. Potential Risks / Side Effects
Moderate/High
- Injection site irritation
- Fatigue
- Headaches
- Flu-like symptoms
- Potential autoimmune symptom aggravation
- Immune dysregulation concerns
- Limited long-term human safety data
8. Half-Life
Thymosin Alpha-1 is commonly discussed as having an estimated plasma half-life of approximately 2 hours.
Despite the relatively short circulating duration, downstream immune signaling effects may persist longer.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Autoimmune disorders
- Use alongside immune-suppressing therapies
- Pregnancy or breastfeeding
- Organ transplant recipients
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Immunology literature
- Peer-reviewed inflammatory and immune regulation journals
CKF Tide Tables 